Publications by authors named "Ay C"
Background: The benefits and risks of extending anticoagulant treatment beyond the first 3 to 6 months in patients with venous thromboembolism (VTE) in clinical practice are not well understood.
Methods: ETNA-VTE Europe is a prospective, noninterventional, post-authorization study in unselected patients with VTE treated with edoxaban in eight European countries for up to 18 months. Recurrent VTE, major bleeding, and all-cause death were the primary study outcomes.
Introduction: Factor XI/XIa (FXI/XIa) has emerged as a potential target for antithrombotic therapy, driven by preclinical evidence showing the role of FXI/XIa inhibition for preventing thrombosis without impeding hemostasis. This is particularly promising for patients at high risk of both thromboembolic events and bleeding, such as patients with end-stage kidney disease (ESKD) on hemodialysis (HD).
Methods: We systematically searched Embase, MEDLINE, and ClinicalTrials.
Background: Patients with cancer treated with immune-checkpoint inhibitors (ICIs) have a substantial risk of venous thromboembolism (VTE). The association between ICI-induced inflammation and hypercoagulability is unclear, and no biomarkers currently exist to stratify VTE risk.
Objectives: The authors sought to determine the association between the early changes in C-reactive protein (CRP) after ICI initiation and the risk of VTE.
Objective: The study was conducted to determine the effect of emotional freedom techniques (EFT) on the severity of premenstrual syndrome (PMS).
Methods: The study was conducted as a randomized controlled trial, with a premenstrual syndrome sample comprising 78 single female students of reproductive age presenting with PMS complaints (40 in the experimental group and 38 in the control group). Students in the experimental group were interviewed individually in the week before their menstrual cycle and received two EFT sessions with a 3-day interval.
Treatment of VTE in the thrombocytopenic cancer patient.
Hematology Am Soc Hematol Educ Program
December 2024
Thrombocytopenia is a frequent complication in patients with cancer, mostly due to the myelosuppressive effects of antineoplastic therapies. The risk of venous thromboembolism (VTE) in patients with cancer is increased despite low platelet counts. The management of cancer-associated VTE in patients with thrombocytopenia is challenging, as the risk of both recurrent VTE and bleeding complications is high.
View Article and Find Full Text PDFArticle Synopsis
- Pregnant women with paroxysmal nocturnal hemoglobinuria (PNH) face high risks of serious blood clots, but eculizumab, a complement inhibitor, can help reduce these risks and improve pregnancy outcomes.
- This study examines two pregnant patients with PNH showing low-level hemolysis, managed solely with preventive anticoagulation and no complement inhibition.
- Both patients had successful pregnancies without thromboembolic issues, suggesting that careful monitoring and anticoagulation might be a viable management approach for certain PNH cases during pregnancy, though more research is necessary.
Background: Treatment sequence in primary immune thrombocytopenia (ITP) is based on national and international recommendations, treatment availability, and physician expertise.
Aim: This article aimed to provide real-world data on treatment sequence and responses to first- and second-line treatments in newly diagnosed and relapsed adult ITP patients.
Methods: We analyzed a cohort of 46 adult ITP patients from the Vienna ITP Biobank, who started first-line therapy within 1 week before their first study visit between February 2016 and March 2023.
Venous thromboembolism (VTE) is the third most common cardiovascular disease. Clonal haematopoiesis (CH) is linked to cardiovascular disease risk, but its potential association with VTE remains poorly understood. We assessed the prevalence of CH in patients with recurrent VTE (n = 107; median age [IQR] 57 [48-63] years, 44.
View Article and Find Full Text PDFIntroduction: The haemophilia joint health score (HJHS) is a tool used to assess joint changes in patients with haemophilia. There is lack of consensus on the interpretation of HJHS scores and their clinical relevance.
Aim: To evaluate available literature reporting HJHS changes over time and assess a possible cut-off value for clinically relevant outcomes and the ideal follow-up for a meaningful score change.
Article Synopsis
- Human saliva contains extracellular vesicles (EVs) that can activate blood coagulation through the presence of extrinsic tenase complexes, which include tissue factor and activated factor VII.
- Individuals with severe hemophilia A, who lack FVIII, have salivary EVs that can compensate for their condition by generating FXa, leading to infrequent oropharyngeal bleeding.
- In contrast, people with severe FVII deficiency lack these functional extrinsic tenase complexes in their saliva, resulting in more frequent oropharyngeal bleedings; however, adding recombinant FVIIa can restore coagulation potential in their saliva.
Objective: To assess the presence of () and species () of newborn-mother pairs using the real time polymerase chain reaction (qRT-PCR).
Method: Subjects were selected from the patients followed in the Neonatology Clinic of Akdeniz University's Faculty of Medicine between the years 2017-2018. First samples collected within 48 hours after birth, and second samples were at six months.
Article Synopsis
- Antiphospholipid syndrome is an autoimmune disorder that causes blood clots and pregnancy issues due to persistent antiphospholipid antibodies.
- Treatment typically involves long-term anticoagulation therapy, which only manages symptoms and doesn't cure the condition.
- A case study shows that a woman treated with CAR T-Cell therapy for lymphoma achieved a lasting reduction in all types of antiphospholipid antibodies, indicating a potential new treatment avenue using immunotherapy.
Article Synopsis
- Biological barriers pose significant challenges in the development of new therapies, as drugs must navigate various protective layers at both the tissue and cellular levels to effectively target specific cells.
- A diverse range of therapeutic options is now available, from small molecules to advanced techniques like gene therapies and monoclonal antibodies, with recent innovations rapidly transforming treatment approaches.
- Notable advancements, such as the FDA approval of new RNA-based therapies and viral-vector gene therapies for hemophilia, exemplify the potential for innovative medicines to address complex diseases and improve patient care.
Background: Patients with end-stage kidney disease (ESKD) are at very high risk for thromboembolism and bleeding. This study aimed to identify small noncoding RNAs (sncRNAs), specifically microRNAs and transfer-RNA (tRNA)-derived fragments (tRFs), as potential novel biomarkers for predicting thromboembolism and bleeding in this high-risk population.
Methods: In this sncRNA discovery research, we leveraged the VIVALDI cohort, consisting of 625 ESKD patients on hemodialysis, to conduct two nested case-control studies, each comprising 18 participants.
Introduction: Patients with chronic kidney disease, especially those with end-stage kidney disease (ESKD) on hemodialysis (HD), are at increased risk for cardiovascular disease (CVD), including myocardial infarction and ischemic stroke. A shortening in telomere length, as a parameter for accelerated vascular aging, is an established biomarker for CVD in the general population. We aimed to elucidate the role of telomere length in ESKD patient on HD and its association with cardiovascular outcomes.
View Article and Find Full Text PDFArticle Synopsis
- Bleeding disorder of unknown cause (BDUC) is diagnosed after ruling out other causes, and this study analyzed data from 375 BDUC patients compared to 100 healthy controls.
- The findings revealed that BDUC patients had lower peak plasmin levels and clot density, indicating potential issues with clot structure, while still showing a higher potential for plasmin generation.
- A model including fibrinogen and plasmin generation parameters effectively distinguished BDUC patients from healthy controls, demonstrating the potential for predictive diagnostics in bleeding disorders.
Article Synopsis
- The hemostatic system and cancer are closely linked, resulting in frequent hemostatic imbalances in cancer patients, particularly concerning bleeding risks associated with therapeutic anticoagulation.
- Despite the known thrombotic risks, there is limited understanding of bleeding risk factors in cancer patients, which can vary based on factors such as hospitalization, tumor type, and medications.
- Current risk assessment models for bleeding in cancer patients on anticoagulation exist but lack validation, and the growing recognition of bleeding risks has led to more studies, although varying study designs complicate the synthesis of findings.
Background: Continuously improving cancer-specific survival puts a growing proportion of cancer patients at risk of major adverse cardiovascular events (MACE), but tailored tools for cardiovascular risk prediction remain unavailable.
Objectives: To assess a broad panel of cardiovascular biomarkers and risk factors for the prediction of MACE and cardiovascular death in cancer patients.
Methods: In total, 2192 patients with newly diagnosed or recurrent cancer were followed prospectively for the occurrence of 2-year MACE and 5-year cardiovascular death.
Article Synopsis
- * In a study of 86 ITP patients and 78 healthy controls, findings showed that ITP patients had significantly slower clot lysis times and higher levels of plasminogen activator inhibitor-1 (PAI-1), while tissue plasminogen activator (tPA) levels were lower.
- * The results suggest that prolonged clot lysis time (CLT) and altered fibrinolysis mechanisms in ITP may contribute to thrombosis risk, with specifically higher tPA-PAI-1 complexes indicating potential
Article Synopsis
- - Thrombotic microangiopathy (TMA) is a group of disorders where small blood vessel clotting causes organ damage, including conditions like thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic syndrome (HUS), each with unique causes and impacts on health.
- - In TMA, inflammation leads to endothelial damage and activates platelet and coagulation processes, often linked to low ADAMTS13 enzyme levels, particularly in cancer patients undergoing chemotherapy, which raises thrombotic risk by increasing the VWF/ADAMTS13 ratio.
- - Treatment focuses on diagnosing the specific cause and may include therapies to inhibit complement activation, supportive care, and plasmapheresis
Article Synopsis
- * In a study of 791 cancer patients undergoing anti-cancer therapies, 17.6% experienced clinically relevant bleeding (CRB), with significant types including gastrointestinal and tumor-related bleeding.
- * Bleeding events, particularly in those without anticoagulation, were linked to higher mortality rates; patients experiencing CRB had a 5.80 times higher risk of all-cause death compared to those who did not bleed.
Article Synopsis
- * The article reviews current evidence and best practices for managing cancer-related VTE, highlighting complexities in treatment for patients with various tumors and specific health issues.
- * Traditional treatments, like vitamin K antagonists and low-molecular-weight heparins, are being supplemented by new options like direct oral anticoagulants, though treatment must be tailored to individual patient circumstances.
Article Synopsis
- Patients with venous thromboembolism (VTE) may suffer from significant anxiety, but this aspect of their health is less researched compared to physical symptoms.
- A study involving 257 patients found that overall anxiety levels decreased over three months, but 23.7% of patients experienced heightened anxiety, especially among older females and those with higher baseline anxiety.
- Factors linked to increased anxiety included being female, being older than 45, having initial anxiety symptoms, while a history of VTE seemed to correlate with lower anxiety, although these findings require further research for conclusive validation.